MSA
MNTA

Mason Street Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Mason Street Advisors’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-44,191
Closed -$1.47M – 1525
2020
Q2 		$1.47M Buy
44,191
+4,661
+12% +$148K 0.03% 650
2020
Q1 		$1.07M Hold
39,530
– – 0.02% 699
2019
Q4 		$780K Buy
39,530
+6,014
+18% +$96.2K 0.01% 986
2019
Q3 		$434K Buy
33,516
+600
+2% +$7.25K 0.01% 1135
2019
Q2 		$410K Buy
32,916
+1,279
+4% +$17K 0.01% 1159
2019
Q1 		$460K Buy
31,637
+1,824
+6% +$23.3K 0.01% 1163
2018
Q4 		$329K Buy
29,813
+6,608
+28% +$92K 0.01% 1178
2018
Q3 		$610K Buy
23,205
+799
+4% +$21.6K 0.01% 1035
2018
Q2 		$458K Buy
22,406
+1,085
+5% +$23.3K 0.01% 1107
2018
Q1 		$387K Buy
21,321
+1,454
+7% +$24.2K 0.01% 1130
2017
Q4 		$277K Buy
19,867
+560
+3% +$7.57K 0.01% 1231
2017
Q3 		$357K Buy
19,307
+2,839
+17% +$47.5K 0.01% 1126
2017
Q2 		$278K Buy
16,468
+1,346
+9% +$20.5K 0.01% 1185
2017
Q1 		$202K Buy
15,122
+1,154
+8% +$18.1K 0.01% 1275
2016
Q4 		$210K Buy
13,968
+1,092
+8% +$14.4K 0.01% 1245
2016
Q3 		$151K Buy
12,876
+513
+4% +$6.03K ﹤0.01% 1297
2016
Q2 		$134K Buy
12,363
+1,331
+12% +$13.7K ﹤0.01% 1299
2016
Q1 		$102K Buy
11,032
+930
+9% +$10K ﹤0.01% 1331
2015
Q4 		$150K Buy
10,102
+876
+9% +$14.7K ﹤0.01% 1207
2015
Q3 		$151K Buy
9,226
+1,012
+12% +$20.7K 0.01% 1162
2015
Q2 		$187K Buy
8,214
+1,791
+28% +$35.7K 0.01% 1113
2015
Q1 		$98K Sell
6,423
-128,583
-95% -$1.67M ﹤0.01% 1298
2014
Q4 		$1.63M Buy
135,006
+207
+0.2% +$2.37K 0.01% 1029
2014
Q3 		$1.53M Sell
134,799
-36
-0% -$411 0.01% 1047
2014
Q2 		$1.6M Buy
134,835
+3,196
+2% +$37.7K 0.01% 1044
2014
Q1 		$1.53M Sell
131,639
-1,681
-1% -$28.5K 0.01% 1045
2013
Q4 		$2.36M Buy
133,320
+126,555
+1,871% +$2.13M 0.02% 852
2013
Q3 		$97K Buy
6,765
+434
+7% +$6.64K ﹤0.01% 1537
2013
Q2 		$95K Buy
+6,331
New +$83.6K ﹤0.01% 1452

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Mason Street Advisors's MNTA Position: Q3 2020 in Review

Mason Street Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 44,191 shares — an estimated $1.47M sold.

Mason Street Advisors first reported a position in MNTA in Q2 2013 and held it in 29 quarters. The position peaked at $2.36M in Q4 2013. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

  • Mason Street Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Mason Street Advisors sold 44,191 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.47M.
  • Mason Street Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
  • Mason Street Advisors's Momenta Pharmaceuticals, Inc. position peaked at $2.36M in Q4 2013.
  • 211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Mason Street Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.